These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Vaccine; 2013 Nov 12; 31(47):5572-8. PubMed ID: 24016810 [Abstract] [Full Text] [Related]
7. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults. Song JY, Lee J, Woo HJ, Wie SH, Lee JS, Kim SW, Kim TH, Jung SI, Noh JY, Choi WS, Cheong HJ, Kim WJ. Hum Vaccin Immunother; 2019 Nov 12; 15(3):710-716. PubMed ID: 30396317 [Abstract] [Full Text] [Related]
8. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M. Pediatr Infect Dis J; 2014 Dec 12; 33(12):1262-9. PubMed ID: 25386965 [Abstract] [Full Text] [Related]
13. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. Wang SY, Liu SZ, Chu K, Zhao Y, Zhu FC, Hu YM, Meng FY, Li JX, Luo L, Yang JY, Liu P, Yu J. Expert Rev Vaccines; 2017 Nov 12; 16(11):1155-1169. PubMed ID: 28870140 [Abstract] [Full Text] [Related]
14. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season. Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB. Int J Environ Res Public Health; 2019 Nov 14; 16(22):. PubMed ID: 31739554 [Abstract] [Full Text] [Related]
15. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M. Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270 [Abstract] [Full Text] [Related]
18. Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study. Lee J, Lee KY, Kim JH, Kim CS, Eun BW, Kim HM, Kim DH, Hong YJ, Choi YY, Jo DS, Ma SH, Kang JH. J Korean Med Sci; 2018 Mar 26; 33(13):e100. PubMed ID: 29573247 [Abstract] [Full Text] [Related]
19. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154 [Abstract] [Full Text] [Related]